We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$868M
AUM Growth
+$59.7M
Cap. Flow
+$69.5M
Cap. Flow %
8.01%
Top 10 Hldgs %
48.78%
Holding
127
New
31
Increased
30
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$14.1M
2
APGE icon
Apogee Therapeutics
APGE
+$11.9M
3
CLYM
Climb Bio
CLYM
+$11.1M
4
ACLX
Arcellx
ACLX
+$8.7M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$8.33M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$9.7M
2
ABSI icon
Absci
ABSI
+$5.82M
3
CYTK icon
Cytokinetics
CYTK
+$5.61M
4
KRYS icon
Krystal Biotech
KRYS
+$4.76M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 65.41%
2 Financials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPS
51
Compass Pathways
CMPS
$1.58B
$3.02M 0.35%
500,512
-527,356
-51% -$4.15M
OLMA icon
52
Olema Pharmaceuticals
OLMA
$1.03B
$2.98M 0.34%
+275,000
New +$2.98M
SANA icon
53
PUT
Sana Biotechnology
SANA
$893M
$2.84M 0.33%
+521,000
New +$4.15M
NXTC icon
54
NextCure
NXTC
$17M
$2.68M 0.31%
140,663
+27,410
+24% +$533K
SWTX
55
DELISTED
SpringWorks Therapeutics
SWTX
$2.64M 0.3%
69,999
-30,001
-30% -$1.26M
BBOT
56
BridgeBio Oncology
BBOT
$699M
$2.56M 0.29%
250,000
– –
BBIO icon
57
BridgeBio Pharma
BBIO
$16.2B
$2.53M 0.29%
100,000
+50,000
+100% +$1.37M
TWST icon
58
CALL
Twist Bioscience
TWST
$5.76B
$2.22M 0.26%
+45,000
New +$1.84M
VRDN icon
59
Viridian Therapeutics
VRDN
$2.13B
$1.95M 0.23%
+150,000
New +$2.08M
NAMSW icon
60
NewAmsterdam Pharma Warrant
NAMSW
$89.1M
$1.92M 0.22%
202,599
– –
WVE icon
61
Wave Life Sciences
WVE
$1.11B
$1.87M 0.22%
375,000
+88,415
+31% +$504K
VIR icon
62
Vir Biotechnology
VIR
$1.58B
$1.78M 0.21%
+200,000
New +$1.92M
RAPT
63
PUT
DELISTED
RAPT Therapeutics
RAPT
$1.66M 0.19%
68,125
-4,013
-6% -$185K
ZYME icon
64
Zymeworks
ZYME
$1.7B
$1.63M 0.19%
+191,127
New +$1.7M
FULC icon
65
CALL
Fulcrum Therapeutics
FULC
$251M
$1.55M 0.18%
250,000
-25,000
-9% -$189K
MRSN
66
DELISTED
Mersana Therapeutics
MRSN
$1.54M 0.18%
30,680
-9,320
-23% -$674K
ARYD
67
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.53M 0.18%
133,500
– –
ADCT icon
68
ADC Therapeutics
ADCT
$155M
$1.5M 0.17%
+474,744
New +$1.89M
KYTX icon
69
Kyverna Therapeutics
KYTX
$443M
$1.5M 0.17%
+200,000
New +$3.06M
IMVT icon
70
CALL
Immunovant
IMVT
$8.08B
$1.43M 0.17%
54,300
-90,100
-62% -$2.56M
ARWR icon
71
Arrowhead Research
ARWR
$12.2B
$1.3M 0.15%
50,000
-70,000
-58% -$1.72M
TNGX icon
72
Tango Therapeutics
TNGX
$4.47B
$1.29M 0.15%
150,274
– –
IOVA icon
73
PUT
Iovance Biotherapeutics
IOVA
$2.29B
$1.2M 0.14%
+150,000
New +$1.61M
NKTX icon
74
Nkarta
NKTX
$165M
$1.18M 0.14%
+200,000
New +$1.42M
PCVX icon
75
CALL
Vaxcyte
PCVX
$8.03B
$1.13M 0.13%
+15,000
New +$1.02M
1 2
3
4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return

Affinity Asset Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Affinity Asset Advisors held 127 positions worth $868M, up 7.4% from $808M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Affinity Asset Advisors deployed $69.5M of net new capital in Q2 2024, opening 31 new positions and adding to 30 existing holdings. Its largest new stake was Climb Bio: 1,670,661 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 71% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $4.42M trimmed.

  • Affinity Asset Advisors's largest Q2 2024 buy was Climb Bio: 1,670,661 shares worth $11.9M.
  • Affinity Asset Advisors added most to Alkermes in Q2 2024, an estimated $14.1M increase.
  • Affinity Asset Advisors's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $4.42M.
  • Affinity Asset Advisors fully exited Apellis Pharmaceuticals in Q2 2024, selling an estimated $9.7M.
  • Affinity Asset Advisors's ten largest holdings make up 49% of its $868M portfolio in Q2 2024.
  • Affinity Asset Advisors opened 31 new positions and closed 29 in Q2 2024.
  • Affinity Asset Advisors's portfolio value rose 7.4% quarter-over-quarter to $868M.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.